CSIMarket Company Name, Ticker, Competitors, else..
 
Nuwellis Inc   (NASDAQ: NUWE)
 
Price: $0.7624 $-0.01 -0.987%
Day's High: $0.8087000250816345 Week Perf: -2.26 %
Day's Low: $ 0.76 30 Day Perf: -45.93 %
Volume (M): 94,256 52 Wk High: $ 6.40
Volume (M$): $ 0 52 Wk Avg: $1.97
Open: $0.77 52 Wk Low: $0.08



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 38
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Nuwellis Inc is a medical device company that specializes in developing and commercializing innovative therapies for patients with chronic heart failure and other fluid overload conditions. The company's flagship product, known as the Aquadex FlexFlow System, is a fluid management system that utilizes ultrafiltration to safely remove excess fluid from patients. This portable system allows patients to manage their fluid balance at home, reducing the need for hospitalization and improving their quality of life. Nuwellis Inc is dedicated to improving patient outcomes and creating more cost-effective solutions for fluid management in the healthcare industry.


   Company Address: 12988 Valley View Road Eden Prairie 55344 MN
   Company Phone Number: 345-4200   Stock Exchange / Ticker: NASDAQ NUWE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ENOV   -1.62%    
GMED   -3.84%    
IART   -6.31%    
MDT   -1.02%    
SYK   -7.14%    
ZBH   -2.07%    
• View Complete Report
   



Management Changes

Nuwellis, Inc. Navigates Leadership Change and Strategic Financial Growth Amidst Fluid Overload Solutions,

Published Mon, Feb 24 2025 9:05 PM UTC

Nuwellis, Inc.: Leadership Transition Amidst Financial Growth and Strategic Vision for the FutureIn a transformative period for Nuwellis, Inc. a key player in the medical technology industry, the company recently announced the retirement of Nestor Jaramillo, Jr. as President and CEO. In a corresponding move, John Erb, the current Chair of the Board, has been appointed as the...
Management Announcement

Nuwellis Bold Leap: Medicare Reimbursement Surge Amid Struggling ROI Performance

Published Mon, Nov 4 2024 1:30 PM UTC

In a move destined to reshape its financial outlook, Nuwellis Inc. announced a staggering 397% daily increase in the reimbursement rate for its Aquadex SmartFlow Therapy, effective January 1, 2025, from the Centers for Medicare and Medicaid Services (CMS). This monumental improvement comes on the heels of a more modest, but still impressive, 112.88% increase over the trailin...
Shares

Nuwellis Secures $5.1 Million Fundraising Through Warrant Exercises, Bolstering Path to Sustain Nasdaq Listing

Published Tue, Nov 5 2024 2:28 PM UTC

On November 5, 2024, Minneapolis-based Nuwellis, Inc. (Nasdaq: NUWE), a prominent player in the medical technology sector, notably specializing in solutions for fluid overload, announced a significant financial milestone. The company revealed the immediate exercise of certain warrants, yielding approximately $5.1 million in gross proceeds.The warrants exercised consist of ap...
Stock Market Announcement

Nuwellis Announces At-The-Market Offering and Receives Continued Listing Approval on Nasdaq

Published Fri, Aug 23 2024 1:00 PM UTC



In a recent press release, medical technology company Nuwellis, Inc. (Nasdaq: NUWE) has revealed its entry into a definitive securities purchase agreement with select institutional investors. Under this agreement, Nuwellis will undertake a registered direct offering priced at-the-market under Nasdaq rules. The offering will consist of 496,901 shares of the Company ...
Stock Market Announcement

Nuwellis, Inc. Successfully Extends Nasdaq Listing, Paving the Way for Transformative Fluid Overload Treatment Innovations

Published Thu, Aug 8 2024 1:00 PM UTC



MINNEAPOLIS, Aug. 08, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a prominent medical technology company dedicated to revolutionizing the lives of individuals suffering from fluid overload, excitedly announced today that The Nasdaq Hearings Panel (Panel) has granted its request to extend its listing on the Nasdaq Stock Market. This decision comes with certain conditions ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.02
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.98
Working Capital Ratio 1.97
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -206.54 $
Revenues (TTM) 49.73 $
Cash Flow (TTM) -
Cash 21.64 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 237,184
Net Income per Employee (TTM) -298,158
Receivable Turnover Ratio (TTM) 6.28
Inventory Turnover Ratio (TTM) 1.43
Asset Turnover Ratio (TTM) 1.19

Profitability Ratios Current
Gross Margin (MRQ) 76.08 %
Operating Margin (MRQ) -160.94 %
Net Margin (MRQ) -245.1 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Nuwellis Inc's Segments
Fluid Overload    222.04 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.